alexa Challenges For Biosimilar Generics | 22456
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars

Vivek Kashyap
ScientificTracks Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X.S1.013
Abstract
Biosimilars are recombinantly produced drugs and are similar to reference biologic. Although, defined, specific and well planned guidelines for Biosimilars are available world-wide, yet the biosimilar drugs face lot of challenge from the patenting strategies from their innovator competitors. Interestingly, most of the innovators not only protect their Biopharmaceuticals in form of product patents but also in form of formulations, delivery systems, preparing methods and their use. However, the biosimilar generics face even a greater challenge from innovator?s devising strategies for developing better and enhanced efficacious Biopharmaceuticals than the existing ones, as the new and improved versions of Biopharmaceuticals can be of concern for biosimilar generics. Therefore it is pertinent for biosimilar generics to understand the patenting strategies of the innovators for Biopharmaceuticals they have developed. In addition, the biosimilar generics need also undertake a comprehensive review of the prosecution strategies of the innovators, which can provide them a good insight to prevent any legal issues.
Biography
Vivek Kashyap, is a Patent Attorney and a registered Patent Agent. He holds PhD and LLB degrees. Dr. Kashyap is presently working as a Senior Associate with Lex Orbis IP Practice, New Delhi. Dr. Kashyap regularly advises national and international clients on patent strategies in India.He was working as an In-House patent attorney with a leading multi-national pharmaceutical company before moving to LexOrbis.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7